We offer a comprehensive suite of immune checkpoint-related products, including high-quality proteins, inhibitor screening ...

Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectivelyFull Year 2025 ...

Cambridge, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the ...

Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively Full Year 2025 target total global revenue of approximately $540 ...

Study reveals surprising connection between common childhood virus CMV and Alzheimer's disease, offering new insights into ...

while being able to culture the B-cells with standard procedures. This allows for the isolation of therapeutic antibodies from rare B-cell clones, and accelerated functional screening and ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand ...

NYSE:DHR) Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research ...

What's on the horizon for the life sciences industry? Robin Johnson, PharmD, Gene Therapy Submissions Lead, inSeption Group What unique challenges do gene therapy submissions face compared to ...